<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03456817</url>
  </required_header>
  <id_info>
    <org_study_id>ATG2017</org_study_id>
    <nct_id>NCT03456817</nct_id>
  </id_info>
  <brief_title>HIgh Dose Thymoglobulin Instead of Cyclosporine With a Low Dose of Thymoglobulin for GVHD Prophylaxis</brief_title>
  <acronym>ATG2017</acronym>
  <official_title>A Phase 2, Open-label Study to Evaluate Graft-vs-host Disease Prophylaxis With High Dose Thymoglobulin, Methotrexate, and Low-dose Cyclosporine in Comparison to Historical/Concurrent Controls Who Received Low Dose Thymoglobulin, Methotrexate, and High-dose Cyclosporine</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>AHS Cancer Control Alberta</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>AHS Cancer Control Alberta</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      The purpose of this study is to find out whether compared to our standard low dose ATG with&#xD;
      CSA, the high dose ATG with low-dose CSA minimizes the chances of relapse and chronic GVHD,&#xD;
      without increasing the chances of other transplant complications.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      There are a number of complications of allogeneic hematopoietic cell transplantation.&#xD;
&#xD;
      The main complications are:&#xD;
&#xD;
        -  Relapse (leukemia or leukemia-like disease returning). This usually leads to death.&#xD;
&#xD;
        -  Acute graft-versus-host disease (GVHD). This may lead to death.&#xD;
&#xD;
        -  Chronic GVHD. This may lead to poor quality of life long-term.&#xD;
&#xD;
      This study is being done to minimize the chances of patients getting relapse and chronic&#xD;
      GVHD, without increasing the chances of getting acute GVHD.&#xD;
&#xD;
      At this time, the standard of care approach to treat this condition would be with:&#xD;
&#xD;
        -  Low dose thymoglobulin (ATG), given on Day -2, -1 and 0.&#xD;
&#xD;
        -  Cyclosporin (CSA), given from Day -1 through to Day 84.&#xD;
&#xD;
        -  Methotrexate, given on Days 1, 3, 6 and 11&#xD;
&#xD;
      CSA reduces the chances of getting acute GVHD, but it does not reduce the chances of getting&#xD;
      chronic GVHD and increases the chances of getting relapse. ATG reduces both acute and chronic&#xD;
      GVHD, and does not increase relapse.&#xD;
&#xD;
      In this study, high dose ATG will be given on days -4, -3, -2, -1 and 0 (instead of only on&#xD;
      days -2, -1 and 0), CSA will be given only from day 21 through 84 (instead of from day -1&#xD;
      through 84), and the routine dose of methotrexate (unchanged) will be given. We think that&#xD;
      this may lead to better outcomes.&#xD;
&#xD;
      Patients will be followed per standard practice of the Alberta Blood and Marrow Transplant&#xD;
      Program for the development of acute and chronic GVHD, and for relapse.&#xD;
&#xD;
      Patients will also be asked to complete a quality of life questionnaire 2 years after the&#xD;
      transplant to assess how their treatment and illness affects their quality of life.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Recruiting</overall_status>
  <start_date type="Actual">July 1, 2020</start_date>
  <completion_date type="Anticipated">September 2023</completion_date>
  <primary_completion_date type="Anticipated">September 2023</primary_completion_date>
  <phase>Phase 2</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Non-Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>moderate/severe chronic GVHD- and relapse-free survival (cGFRS) at 2 years post transplant</measure>
    <time_frame>2 years</time_frame>
    <description>cGRFS will be compared between the study patients and the historical/concurrent controls using a Cox proportional hazards model to determine if administering high dose ATG + MTX and low dose CSA will be associated with improved cGRFS compared to historical/concurrent controls (4.5 mg/kg ATG + MTX + CSA).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>quality of life</measure>
    <time_frame>approximately 2 years (21 to 27 months) post transplant</time_frame>
    <description>each scale (domain) of the short form-36 (SF36) questionnaire will be compared between the high dose ATG group and the control group using Mann-Whitney-Wilcoxon signed rank test to determine if quality of life (QOL) at 2 years posttransplant will be better in the high dose ATG patients compared to the controls (due to the reduction of cGVHD).</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">200</enrollment>
  <condition>Graft-versus-host-disease</condition>
  <condition>Relapse</condition>
  <arm_group>
    <arm_group_label>Treatment Arm - High dose ATG, Low dose CSA</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>High dose ATG will be infused on days -4, -3, -2, -1 and 0. Before each infusion of ATG (thymoglobulin), patient will receive medications preventing side effects from the ATG, including diphenhydramine (Benadryl), an antipyretic (ibuprofen or acetaminophen) and methylprednisolone (Solumedrol). The high dose ATG will be given into patient's vein via central venous catheter. Each infusion of ATG will take 4-8 hours. CSA (cyclosporine A) will be given from day 21. Standard dose methotrexate will be given.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Control Arm - Standard of care</arm_group_label>
    <arm_group_type>Other</arm_group_type>
    <description>Low dose ATG (thymoglobulin) will be infused on days -2, -1 and 0, and CSA (cyclosporine A) will be given from day -1 through day 84. Standard dose methotrexate will also be given.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Treatment Arm - high dose ATG</intervention_name>
    <description>Patients agreeing to high dose ATG will be treated with 2 mg/kg daily on days -4 to 0. On days -4, -3 &amp; -2, ATG will be infused after fludarabine &amp; busulfan infusion. ATG will be infused over a minimum of 6 hrs on day -4 &amp; over at least 4 hrs on days -3, -2, -1 &amp; 0. Dose is based on actual body wt, &amp; rounded to nearest vial-Thymoglobulin is supplied in 25 mg vials, except if rounding would result in &gt;5% difference from calculated dose. Foothills Medical Center Unit 57 standard practice followed for ATG infusion. ATG premeds include methylprednisolone, diphenhydramine, and an antipyretic. Meperidine 25-50 mg IVPB every 4 hours will be given as needed for rigors. MTX is given 15 mg/m2 IV on day +1 &amp; 10 mg/m2 on days +3, +6 &amp; +11 posttransplant. First dose of methotrexate is given on day +1, at least 24 hrs following end of infusion of stem cell product.</description>
    <arm_group_label>Treatment Arm - High dose ATG, Low dose CSA</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Control Arm - standard of care</intervention_name>
    <description>The historical controls will have received and the concurrent controls will receive our standard GVHD prophylaxis, ie, ATG 4.5 mg/kg i.v. (0.5 mg/kg on day -2, 2.0 mg/kg on day -1 and 2.0 mg/kg on day 0), MTX (15 mg/m2 i.v. on day 1 and 10 mg/m2 i.v. on days 3, 6 and 11) and CSA (2.5 mg/kg twice a day i.v. starting from day -1, adjusting dose to target trough plasma CSA levels of 200-400 microg/L, switching to oral formulation before discharge from peritransplant hospitalization, targeting the trough plasma levels of 200-400 microg/L until day 56, and tapering to zero between day 56 and 84).</description>
    <arm_group_label>Control Arm - Standard of care</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Inclusions:&#xD;
&#xD;
               1. First allogeneic HCT, performed for a hematologic malignancy, using&#xD;
                  filgrastim-mobilized peripheral blood stem cells (PBSC).&#xD;
&#xD;
               2. Conditioning with fludarabine 50 mg/m2 daily on day -6 to -2, busulfan&#xD;
                  approximately 3.2 mg/kg daily on day -5 to -2 with PK adjustment (target AUC of&#xD;
                  3750 uM*min/L) and total body irradiation (TBI) 2 Gy daily on day -1 and 0&#xD;
                  (before graft infusion), ie, our standard myeloablative conditioning.72&#xD;
&#xD;
               3. Planned GVHD prophylaxis with our standard of low-dose ATG (4.5 mg/kg) + MTX +&#xD;
                  high-dose CSA.&#xD;
&#xD;
               4. HLA matched sibling donor, or â‰¥7/8 HLA allele-matched unrelated donor.&#xD;
&#xD;
               5. Age &gt;17 years.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          1. Nonmyeloablative conditioning.&#xD;
&#xD;
          2. Cord blood or marrow graft.&#xD;
&#xD;
          3. Previous autologous or allogeneic HCT.&#xD;
&#xD;
          4. Bilirubin &gt;1.5-fold above upper normal limit (UNL), ALT or AST &gt;2.0-fold above UNL, or&#xD;
             alkaline phosphatase &gt;2.5-fold above UNL.&#xD;
&#xD;
          5. HIV positive by a serologic test that includes detection of both antibody and antigen)&#xD;
&#xD;
          6. Increased risk of tuberculosis, defined as patient requiring an anti-tuberculosis drug&#xD;
             peritransplant. All patients with a history of tuberculosis (active or latent) or&#xD;
             contact with a person with active tuberculosis will be evaluated by an infectious&#xD;
             disease specialist to determine whether treatment or prophylaxis of tuberculosis with&#xD;
             an anti-tuberculosis drug peritransplant is needed. The infectious disease specialist&#xD;
             will order tests (eg, Mantoux tuberculin skin test or interferon gamma release test)&#xD;
             as needed to arrive at the decision on whether an anti-tuberculosis drug&#xD;
             peritransplant is needed.&#xD;
&#xD;
          7. High risk of cytomegalovirus (CMV) disease or recurrent CMViremia based on donor&#xD;
             negative AND recipient positive CMV serostatus&#xD;
&#xD;
          8. High risk of PTLD based on donor positive AND recipient negative Epstein-Barr virus&#xD;
             (EBV) serostatus (EBNA1 or VCA IgG)&#xD;
&#xD;
          9. Hypersensitivity to rabbit blood protein, Thymoglobulin or a Thymoglobulin excipient.&#xD;
&#xD;
         10. Contraindication to methotrexate:&#xD;
&#xD;
               1. Hypersensitivity to methotrexate or to any ingredient in the formulation or&#xD;
                  component of the container.&#xD;
&#xD;
               2. Females of childbearing potential who are pregnant, breastfeeding or unwilling to&#xD;
                  use adequate contraception from the time of enrolment until at least day 100&#xD;
                  posttransplant.&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Jan Storek, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Tom Baker Cancer Centre</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Jan Storek, MD</last_name>
    <phone>403-210-8630</phone>
    <email>jstorek@ucalgary.ca</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Amy Abel</last_name>
    <email>Amy.Abel@ahs.ca</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Tom Baker Cancer Centre</name>
      <address>
        <city>Calgary</city>
        <state>Alberta</state>
        <zip>T2N 4N2</zip>
        <country>Canada</country>
      </address>
    </facility>
    <status>Recruiting</status>
    <contact>
      <last_name>Jan Storek, MD</last_name>
      <email>jstorek@ucalgary.ca</email>
    </contact>
    <contact_backup>
      <last_name>Amy Abel</last_name>
      <email>Amy.Abel@ahs.ca</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>Canada</country>
  </location_countries>
  <verification_date>October 2021</verification_date>
  <study_first_submitted>March 1, 2018</study_first_submitted>
  <study_first_submitted_qc>March 1, 2018</study_first_submitted_qc>
  <study_first_posted type="Actual">March 7, 2018</study_first_posted>
  <last_update_submitted>October 18, 2021</last_update_submitted>
  <last_update_submitted_qc>October 18, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">October 25, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Graft vs Host Disease</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

